Ovid Therapeutics INC

Ovid Therapeutics reported Q2 2026 business updates and financial results, highlighting progress in its OV4071 and OV329 programs, a strategic soticlestat transaction, and strengthened leadership.

Ovid Therapeutics announces the appointment of Charles Carter as Chief Financial Officer and the departure of Jeffrey Rona, effective July 6, 2026.

Ovid Therapeutics Inc. announced the results of its annual meeting of stockholders held on June 10, 2026, including the election of a director and advisory approval of executive compensation.

Ovid Therapeutics Inc. announced the appointment of Dr. Anna Greka to its Board of Directors, effective June 15, 2026, expanding the board to seven members.

Ovid Therapeutics announced first quarter 2026 business updates and financial results, highlighting progress in its OV329 and OV4071 programs and a strengthened balance sheet.

Ovid Therapeutics Inc. announced the expiration of its Series A Warrants, resulting in the exercise of most warrants and raising approximately $53.9 million in gross proceeds.

Ovid Therapeutics Inc. filed its Form 10-Q for the period ended June 30, 2026, detailing continued operating losses and a strong reliance on capital raises to fund its biopharmaceutical development.

Ovid Therapeutics Inc. reported its first quarter 2026 financial results, highlighting increased research and development expenses and significant proceeds from private placements and warrant exercises.

Ovid Therapeutics reported a net loss of $12.2 million for Q3 2025, but a recent $75.7 million private placement significantly extends its cash runway.

Ovid Therapeutics reported increased net losses and substantial doubt about its ability to continue as a going concern, despite a one-time revenue boost from a licensing agreement.

Ovid Therapeutics reports a net loss of $10.2 million for Q1 2025, focusing on pipeline development and managing cash runway.

Ovid Therapeutics' third quarter 2024 report highlights ongoing research and development efforts, alongside a strategic restructuring to extend its cash runway.

Ovid Therapeutics Inc. reported a reduced net loss for 2025, driven by increased revenue and successful capital raises, as it advances its pipeline of brain disorder treatments.

Ovid Therapeutics files an amendment to its annual report to include information required by Items 10 through 14 of Part III, related to directors, executive officers, compensation, and corporate governance.

Ovid Therapeutics' 2024 10-K filing details the company's focus on developing small molecule medicines for brain conditions, pipeline advancements, and financial strategy for long-term stockholder value.

Ovid Therapeutics' 10-K filing details its capital structure, pipeline progress, and strategic focus on developing novel treatments for epilepsies and neurological disorders with seizure symptoms.

Ovid Therapeutics Inc. reports that Chief Financial Officer Charles Ross Carter was awarded 50,000 restricted stock units on July 6, 2026.

Ovid Therapeutics Inc. reports a Form 4 filing detailing the grant of stock options to Director Anna Greka.

Ovid Therapeutics Inc. reports that Director Stelios Papadopoulos was awarded restricted stock units (RSUs) valued at $45,000 as part of the company's Non-Employee Director Compensation Policy.

Ovid Therapeutics Inc. director Bart Friedman reported the acquisition of 8,789 restricted stock units (RSUs) as part of his compensation.

Ovid Therapeutics Inc. reports that Director Kevin Joseph Fitzgerald was granted restricted stock units (RSUs) as part of his compensation.

Ovid Therapeutics Executive Chairman Jeremy Levin exercised Series A Warrants to acquire 47,333 shares of common stock at $1.40 per share.

Ovid Therapeutics Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026.

Ovid Therapeutics calls a Special Meeting to approve a significant increase in authorized common stock and the issuance of shares related to a recent $80.8 million PIPE financing.

Ovid Therapeutics Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Ovid Therapeutics is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and improve stock marketability.

Ovid Therapeutics Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Ovid Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.

ADAR1 Capital Management, LLC, along with related entities and individuals, has filed a Schedule 13G amendment indicating a reduction in their beneficial ownership of Ovid Therapeutics Inc. common stock to below 5%.

RA Capital Management and its affiliates now beneficially own 9.9% of Ovid Therapeutics' common stock, primarily through warrants and direct holdings, as of June 30, 2026.

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 11,812,241 shares, representing 6.3% of Ovid Therapeutics Inc.'s common stock as of June 30, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 4.99% of Ovid Therapeutics Inc. common stock.

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 4.15% of Ovid Therapeutics Inc. common stock as of June 30, 2026.

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 12,773,577 shares, representing 7.3% of Ovid Therapeutics Inc.'s common stock as of March 31, 2026.